Adverse Reactions Due to Directly Observed Treatment Strategy Therapy in Chinese Tuberculosis Patients: A Prospective Study

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Lv, Xiaozhen ^a,b   Tang, Shaowen ^a,c   Xia, Yinyin ^d   Wang, Xiaomeng ^e   Yuan, Yanli ^f   Hu, Daiyu ^g   Liu, Feiying ^h   Wu, Shanshan ^a   Zhang, Yuan ^a   Yang, Zhirong ^a   Tu, Dehua ⁱ   Chen, Yixin ^j   Deng, Peiyuan ^j   Ma, Yu ^k   Chen, Ru ^a   Zhan, Siyan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f Center for Disease Control and Prevention of Jilin Province   (China)

^g Chongqing Municipal Center for Disease Control and Prevention   (China)

^h Center for Disease Control and Prevention in Guangxi Zhuang Autonomous Region   (China)

ⁱ Beijing Institute for Tuberculosis Control   (China)

^j Center for Drug Reassessment State Food and Drug Administration   (China)

^k CAPITAL MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ARTHRALGIA; ARTICLE; AUDITORY NERVE DAMAGE; BLOOD TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHINA; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HEALTH CARE QUALITY; HUMAN; HYPOKALEMIA; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEUROLOGIC DISEASE; NEUROPATHY; OPTIC NERVE LESION; OUTCOME ASSESSMENT; PERIPHERAL NERVE INJURY; POPULATION RESEARCH; PROGNOSIS; PROSPECTIVE STUDY; SHORT COURSE THERAPY; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT;

ADULT; ANTITUBERCULAR AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84878665734     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065037     Document Type: Article

References (35)

1. World Health Organization (2012) Global Tuberculosis Report 2012: The burden of disease caused by TB. Geneva, Switzerland. 10-17 p.
2. Xia YY, Hu DY, Liu FY, Wang XM, Yuan YL, et al. (2010) Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS). BMC Public Health 10: 267.
3. China Tuberculosis Control Collaboration, (2004) The effect of tuberculosis control in China. Lancet 364: 417-422.
4. World Health Organization (2002) An expanded DOTS framework for effective tuberculosis control. Stop TB Communicable Diseases. Geneva: WHO Press. 1-20 p.
5. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, et al. (2003) Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167: 1472-1477.
6. Gholami K, Kamali E, Hajiabdolbagh Mi, Shalviri G, (2006) Evaluation of anti-tuberculosis induced adverse reactions in hospitalized patients. Pharm Prac 4: 134-138.
7. Javadi MR, Shalviri G, Gholami K, Salamzadeh J, Maghooli G, et al. (2007) Adverse reactions of anti-tuberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol Drug Saf 16: 1104-1110.
8. Ormerod LP, Horsfield N, (1996) Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tubercle and Lung Disease 77: 37-42.
9. Arbex MA, Varella Mde C, Siqueira HR, Mello FA, (2010) Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 36: 626-640.
10. Vieira DE, Gomes M, (2008) Adverse effects of tuberculosis treatment: experience at an outpatient clinic of a teaching hospital in the city of São Paulo, Brazil. J Bras Pneumol 34: 1049-1055.
11. Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A, (2008) Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. Pak J Pharm Sci 21: 185-94.
12. Gülbay BE, Gürkan OU, Yildiz OA, Onen ZP, Erkekol FO, et al. (2006) Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 100: 1834-1842.
13. Schaberg T, Rebhan K, Lode H, (1996) Risk factors for side-effects of isoniazid, Damrifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 9: 2026-2030.
14. Marra F, Marra CA, Bruchet N, Richardson K, Moadebi S, et al. (2007) Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 11: 868-875.
15. Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, et al. (2008) Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc 58: 531-536.
16. Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K, et al. (2004) Adverse drug reactions observed during DOTS. J Commun Dis 36: 251-259.
17. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, et al. (1995) Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subful-minant liver failure during antituberculous treatment including isoniazid. Hepatology 21: 929-932.
18. Awofeso N (2008) Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull World Health Organ 86: B-D.
19. Kaona FA, Tuba M, Siziya S, Sikaona L, (2004) An assessment of factors contributing to treatment adherence and knowledge of TB transmission among patients on TB treatment. BMC Public Health 4: 68.
20. Maciel EL, Guidoni LM, Favero JL, Hadad DJ, Molino LP, et al. (2010) Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. J Bras Pneumol 36: 232-238.
21. Xia YY, Zhan SY, (2007) Systematic review of anti-tuberculosis drug induced Adverse reactions in China. Zhonghua Jie He He Hu Xi Za Zhi 30: 419-423.
22. Edwards IR, Aronson JK, (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259.
23. The UPPSALA MONITORING CENTRE: The use of the WHO-UMC system for standardized case causality assessment. Available: http://who-umc.org/Graphics/24734.pdf. Accessed 2012 March 5.
24. Shang P, Xia Y, Liu F, Wang X, Yuan Y, et al. (2011) Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China. PLoS ONE 7: e21836.
25. World Health Organization (2009) Treatment of Tuberculosis: Guidelines-4th ed. Geneva, Switzerland: 58 p.
26. China Public Health Science Database Center (2008) Report of tuberculosis monitoring in 2008: the distribution of gender and age in new smear positive patients.
27. Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, et al. (2008) Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64: 673-681.
28. Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW, (2004) Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care13: 306-314.
29. Gonzalez Montaner LJ, Dambrosi A, Manassero M, Dambrosi VM, (1982) Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle 63: 291-294.
30. Caminero JA, (2010) Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 14: 382-90.
31. WHO (2007) Tuberculosis fact sheets. Available: http://www.who.int/mediacentre/factsheets/fs104/en/. Accessed 2012 May 17.
32. World Health Organization (2012) Global Tuberculosis Report 2012: TB case notifications and treatment outcomes. Geneva, Switzerland. 40 p.
33. Patel AM, McKeon J, (1995) Avoidance and Management of Adverse Reactions to Antituberculosis Drugs. Drug Safety 12: 1-25.
34. Tu DH, Chen MT (2011) Adverse reactions reporting and monitoring. In Anti-tuberculosis Drugs Management Manual. Wang LX and Chen MT (eds). People's Military Medical Press: Beijing, 68-72 p.
35. China AIDS epidemic 2011. The Ministry of Health of the People's Republic of China. Available: http://download.chinagate.cn/ch/pdf/aizibing.pdf. Accessed 2012 Nov 20.